Abstract
As one of the most fatal malignancies, pancreatic ductal adenocarcinoma (PDAC) has significant resistance to the currently available treatment approaches. Gemcitabine, the standard chemotherapeutic agent for locally advanced and metastatic PDAC, has limited efficacy, which is attributed to innate/acquired resistance and the activation of prosurvival pathways. Here, we investigated the in vitro efficacy of I-BET762, an inhibitor of the bromodomain and extraterminal (BET) family of proteins, in treating PDAC cell lines alone and in combination with gemcitabine (GEM). The effect of these two agents was also examined in xenograft PDAC tumors in mice. We found that I-BET762 induced cell cycle arrest in the G0/G1 phase and cell death and suppressed cell proliferation and metastatic stem cell factors in PDAC cells. In addition, the BH3-only protein Bim, which is related to chemotherapy resistance, was upregulated by I-BET762, which increased the cell death triggered by GEM in PDAC cells. Moreover, GEM and I-BET762 exerted a synergistic effect on cytotoxicity both in vitro and in vivo. Furthermore, Bim is necessary for I-BET762 activity and modulates the synergistic effect of GEM and I-BET762 in PDAC. In conclusion, we investigated the effect of I-BET762 on PDAC and suggest an innovative strategy for PDAC treatment.
Highlights
Pancreatic ductal adenocarcinoma (PDAC) is the 12th most prevalent malignancy worldwide[1]
To determine the influence of bromodomain and extraterminal (BET) inhibitors, pancreatic ductal adenocarcinoma (PDAC) cells were treated with JQ-1 and I-BET762
The results revealed that I-BET762 and JQ-1 noticeably triggered apoptosis in PDAC cells (Fig. 1D)
Summary
Pancreatic ductal adenocarcinoma (PDAC) is the 12th most prevalent malignancy worldwide[1]. Twenty percent of patients receiving a diagnosis of PDAC qualify for surgery[6]. The five-year survival rates for patients with PDAC after surgical resection are only approximately twenty percent, even with GEM supplementation[13]. The bromodomain and extraterminal (BET) family participates in recognizing ε-N-acetylated lysine residues in histone tails[14]. Other mediators besides BRD4 co-occupy the promoters and enhancers of stimulated genes[16] These mediators are enriched at numerous enhancer sequences, commonly named superenhancers[17]. Study has shown that I-BET762 downregulates c-Myc, and dephosphorylation of ERK1/2 leading to proliferation inhibition in pancreatic cancer cells[23]. The influence of BET inhibitors together with GEM on PDAC was explored both in vitro and in vivo
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.